MentionFox
Home › Executive changes › AtaiBeckley Inc.
Leadership changes · ATAI · SEC Form 8-K, Item 5.02

Leadership changes at AtaiBeckley Inc. (2026)

Before you join, sell to or invest in AtaiBeckley Inc.

MentionFox check on AtaiBeckley Inc.: no red flags found in 3 sources (checked 14 November 2026). mentionfox.com/c/executive-changes/ataibeckley

Check AtaiBeckley Inc. before you join, sell or invest Free, no sign-up: every record on file, each linked to its source.

What do you want to do about AtaiBeckley Inc.?

Who joined and who left AtaiBeckley Inc. (ATAI)? 2 appointments reported from 2026-01-08 to 2026-09-11, each cited to the company's own filing.

Michael Faerm was named Chief Financial Officer of AtaiBeckley Inc. As of November 14, 2026, AtaiBeckley Inc. has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from January 8, 2026 to September 11, 2026, naming 2 appointments (Form 8-K, February 19, 2026).

29 companies changed executives this week, 1 had other signals.

Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.

ONITY GROUP INC.announced the departure of its Chief Investment Officer
Adicet Bio, Inc.announced the departure of its Director
MAMMOTH ENERGY SERVICES, INC.announced the departure of its Chief Operating Officer
CERENOME, INC.named a new Director
Cohen & Co Inc.named a new Chief Executive Officer
Check one company free All companies that changed executives this week

Apeiron Investment Group Ltd. also filed stake reports on 2 other companies ↓

Sell to companies like AtaiBeckley Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Opens in a new tab. No signup.

Key facts

  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-09-11
  • · In / out: In · Person: Michael Faerm · Role: Chief Financial Officer · 8-K, 2026-02-19
  • · In / out: Reported · Person: not named in the filing · 8-K, 2026-01-08
Changes4
In (appointed)2
Latest filing2026-09-11

AtaiBeckley Inc. reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-01-08 to 2026-09-11. They name 1 person. Every row below is cited to the filing it comes from, and this page adds each new change as AtaiBeckley Inc. files it.

Also on the record for AtaiBeckley Inc.

DateRecordFigureOur pageSource
September 14, 2026Stake report, Schedule 13D/A, by Apeiron Investment Group Ltd.—5%+ stakesSource
September 11, 2026Acquired by Eli Lilly and Company—AcquisitionSource
July 27, 2026Stake report, Schedule 13G, by BlackRock, Inc.6.8% of the class5%+ stakesSource
July 17, 2026Stake report, Schedule 13D/A, by Apeiron Investment Group Ltd.15.4% of the class5%+ stakesSource

Selling to them or working with them? See who runs AtaiBeckley Inc. now and the warning signs.

Free to see. No signup.

Keep reading

More on AtaiBeckley Inc. and the records around it.

AtaiBeckley Inc. elsewhere on the record

Companies that share a holder

Want the whole picture on AtaiBeckley Inc.?

Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)

A Full Report on AtaiBeckley Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on AtaiBeckley Inc. covers

  1. The Short Answer

  2. Which Company This Is

  3. What They Do, And How The Money Works

  4. Who Runs It, And How To Reach Them

  5. The Money: Funding, Valuation, Runway

  6. Who Pays Them, And Who They Are Up Against

  7. Warning Bells

  8. Sources

    6 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

See a sample report

First screen of a real sample Full Report on EchoStar: the verdict, 17 sections, 63 cited sources, built 2026-10-21A real finished report, first screen. Opens in a new tab.

Timeline

FiledIn / outPersonRoleEffectiveSource
2026-09-11Reportednot named in the filing8-K, 2026-09-11
2026-02-19InChief Financial Officer8-K, 2026-02-19
2026-02-19In8-K, 2026-02-19
2026-01-08Reportednot named in the filing8-K, 2026-01-08

Who leads AtaiBeckley Inc., as last reported?

For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.

Selling to AtaiBeckley Inc.?

New leaders reset buying decisions — get the Full Report on AtaiBeckley Inc.: who runs it, how the money works and what to watch, every claim linked to its source.

Get the Full Report

Watch AtaiBeckley Inc.

Hiring for a seat like this?

Find people with the same kind of experience as the Chief Financial Officer at AtaiBeckley Inc., with the record behind each one.

Find candidates like Chief Financial Officer at AtaiBeckley Inc.

Every change, in the filing's words

Filed 2026-09-11 · 8-K

Reported

In accordance with the terms of the Merger Agreement, at the Effective Time, each of the members of the Company's Board of Directors, each of whom was a director of the Company as of immediately prior to the Effective Time, resigned and ceased to be a director of the Company and a member of any committee of the Company's Board of Directors.

Also stated in this filing

  • In accordance with the terms of the Merger Agreement, at the Effective Time, Christopher Anderson and Jonathan R. Haug, the directors of Merger Sub immediately prior to the Effective Time, became directors of the Company.
  • In accordance with the terms of the Merger Agreement, at the Effective Time, each of the executive officers of the Company resigned from their positions as officers of the Company.
  • In accordance with the terms of the Merger Agreement, at the Effective Time, the officers of Merger Sub immediately prior to the Effective Time, Jonathan R. Haug as President, Steffanie Lim-Ho as Treasurer, Christopher Anderson as Secretary, Jonathan Groff as Assistant Secretary, Jamie Burnett as Assistant Secretary and Katie Lodato as Assistant Treasurer, became the officers of the Company.
  • On September 10, 2026, the Board of Directors of the Company approved the grant of a retention bonus to Gerd Kochendoerfer in the amount of $194,000, less applicable deductions and withholdings.
  • Subject to Mr. Kochendoerfer's continued employment with the Company through the Effective Time, the retention bonus will be paid to him on the first regularly scheduled payroll date following the Closing Date that is at least 10 days after the Closing Date.
Filed 2026-02-19 · 8-K

Appointed: Michael Faerm, Chief Financial Officer

On February 15, 2026, the Board of Directors of AtaiBeckley Inc. (the "Company") appointed Michael Faerm as the Company's Chief Financial Officer, effective as of the date Mr. Faerm commences employment with ATAI Life Sciences US, Inc. ("ATAI US"), which is expected to occur on March 9, 2026 (the "Appointment Date").

Appointed: Michael Faerm

In connection with his appointment, effective as of the Appointment Date, Mr. Faerm has been designated as the Company's principal financial officer.

Also stated in this filing

  • Mr. Faerm succeeds Anne Johnson, who will cease serving as Chief Financial Officer, and will serve as the Company's Chief Accounting Officer and remain designated as the Company's principal accounting officer, in each case effective as of the Appointment Date.
  • Michael Faerm, 59, most recently served as a consulting Chief Financial Officer to various biopharmaceutical companies through his firm, MEF Consulting LLC, from February 2025 to February 2026.
  • From May 2024 to February 2025, Mr. Faerm served as Chief Financial Officer of Viracta Therapeutics, Inc., a precision oncology company.
  • From October 2023 to March 2024, Mr. Faerm served as Interim Chief Financial Officer of Harpoon Therapeutics, Inc., an immunotherapy company.
  • From April 2021 to March 2023, Mr. Faerm served as Chief Financial Officer of Artiva Biotherapeutics, Inc., a natural killer (NK) cell-based therapy company.
  • From 2019 to 2021, Mr. Faerm served as a consulting and interim Chief Financial Officer and Chief Business Officer to various biopharmaceutical companies through his firm, MEF Consulting LLC.
Filed 2026-01-08 · 8-K

Reported

On January 6, 2026, Cosmo Feilding-Mellen resigned from the board of directors (the "Board") of AtaiBeckley Inc. (the "Company"), effective immediately.

Also stated in this filing

  • Mr. Feilding-Mellen's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies and practices.

Tools for this story

Each opens in a new tab, filled in for AtaiBeckley Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Not for employment, credit or tenancy decisions. MentionFox research is for sales, partnership and investor research. Permitted use

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/ataibeckley
Last updated 2026-11-14
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3 · SEC filing 4
Who joined AtaiBeckley Inc.? Leadership changes (2026). MentionFox, 2026-11-14. https://mentionfox.com/executive-changes/ataibeckley